| U0618 |
Ubenimex |
10 mg |
$48.40 |
| |
Bestatin |
50 mg |
$200.10 |
| |
C16H24N2O4 FW 308.37 [58970-76-6] |
100 mg |
$310.50 |
| |
Ubenimex is an antitumor agent effective against murine syngeneic tumors including mouse |
|
|
| |
colon 26 and C1498 leukemia. It was found to be active against MNNG-induced rat tumor |
|
|
| |
by oral administration. It also inhibits leucine aminopeptidase and aminopeptidase B in cell |
|
|
| |
membrane, in addition to modulating PKC in K562 cells and inducing apoptosis. |
|
|
| |
Sekine K, Fujii H, Abe F. Leukemia. 13:729-34 (1999). |
|
|
| |
Tsukagoshi S. Gan To Kagaku Ryoho. 14:2385-91 (1987). |
|
|
| |
Ebihara K, Abe F, Yamashita T et al. J Antibiot. 39:966-70 (1986). |
|
|
| |
|
|
|
| U5232 |
Uniconazole |
5 g |
$39.20 |
| |
C15H18ClN3O FW 291.78 [83657-22-1] |
10 g |
$50.40 |
| |
Triazole plant growth inhibitor that suppresses the gibberelin and sterol |
100 g |
$302.40 |
| |
biosynthesis. The pesticide is suspected of being a carcinogen. |
|
|
| |
Uniconazole P; pesticide tolerances. Federal Register (2008), 73(173), 51732-51736. |
|
|
| |
|
|
|
| U5233 |
Universal TT epitope P2 (830-844) |
1 mg |
$71.70 |
| |
C80H129N19O23 FW 11725.03 |
2 mg |
$121.90 |
| |
Addition of this peptide to vaccines enhances the efficacy of the immune |
5 mg |
$215.00 |
| |
response to malaria prophylaxis. |
|
|
| |
Fryauff DJ, Mouzin E and Church LW. et. al.Vaccine. 17: 59-63 (1999). |
|
|
| |
|
|
|
| U6118 |
Uperolein |
1 mg |
$78.80 |
| |
C57H79N13O16S FW 1234.42 |
2 mg |
$134.40 |
| |
A physalaemin-like endecapeptide that is selective for Neurokinin 1 receptor. |
5 mg |
$236.50 |
| |
Dike A, Cowsik SM. J Struct Biol. 156: 442-52 (2006). |
|
|
| |
|
|
|
| U6901 |
Uracil |
10 g |
$17.10 |
| |
C4H4N2O2 FW 112.09 [66-22-8] |
25 g |
$26.00 |
| |
Used in the treatment of metastatic colorectal cancer and hormone refractory |
100 g |
$43.10 |
| |
prostate cancer. |
|
|
| |
Lin JK, Fan FS, Yen CC et al. Jpn J Clin Oncol. 30:510-4 (2000). |
|
|
| |
Nishimura K, Nomomura N, Ono Y et al. Oncology. 60:49-54 (2001). |
|
|
| |
|
|
|
| U6802 |
Urapidil hydrochloride |
500 mg |
$55.20 |
| |
C20H29N5O3.HCl FW 423.93 [64887-14-5] |
1 g |
$89.70 |
| |
|
5 g |
$345.00 |
| |
|
|
|
| U6854 |
Urocortin, human |
0.5 mg |
$179.20 |
| |
C204H337N63O64 FW 4696.3 [171543-83-2] |
1 mg |
$304.60 |
| |
A CRF-related peptide involved in the relaxation of pulmonary arteries. |
2.5 mg |
$537.60 |
| |
Lau CW, Chan YC, Yao X. Eur J Pharmacol. 488:169-172 (2004). |
|
|
| |
|
|
|
| U6855 |
Urocortin, rat |
0.5 mg |
$179.20 |
| |
C206H338N62O64 FW 4707.37 |
1 mg |
$304.60 |
| |
|
2.5 mg |
$537.60 |
| |
|
|
|
| U6856 |
Urocortin II, human |
0.5 mg |
$250.90 |
| |
C194H338N63O54S1 FW 4449.31 |
1 mg |
$426.50 |
| |
A selective CRF receptor type 2 agonist that enhances contractility of ventricular |
2.5 mg |
$752.60 |
| |
mycocytes in rabbit. |
|
|
| |
Yang LZ, Kockskamper J, Heinzel FR. et. al. Cardiovasc Res. 69: 402-11 (2006). |
|
|
| |
|
|
|
| U6858 |
Urocortin II, mouse |
0.5 mg |
$250.90 |
| |
C187H320N56O50 FW 4152.98 |
1 mg |
$426.50 |
| |
|
2.5 mg |
$752.60 |
| |
|
|
|
| |
|
|
|
| U6859 |
Urocortin III, human |
0.5 mg |
$250.90 |
| |
C185H307N53O50S2 FW 4137.96 |
1 mg |
$426.50 |
| |
A selective CRF receptor type 2 agonist that exhibits bronchorelaxant and |
2.5 mg |
$752.60 |
| |
anti-inflammatory activities. |
|
|
| |
Moffatt JD, Lever R, Page CP. FASEB J. 20:1877-9 (2006). |
|
|
| |
|
|
|
| U6860 |
Urocortin III, mouse |
0.5 mg |
$250.90 |
| |
C186H312N52O52S2 FW 4173.01 |
1 mg |
$426.50 |
| |
|
2.5 mg |
$752.60 |
| |
|
|
|
| |
|
|
|
| U6857 |
Urodilatin CCC/ANP-95-126 |
1 mg |
$322.60 |
| |
C145H234N52O44S3 FW 3506.0 [115966-23-9] |
|
|
| |
A renal natriuretic peptide that has been shown to possess a vasodilatory effect in pulmonary |
|
|
| |
circulation. |
|
|
| |
Schermuly RT, Weissman N, Enke B et al. Am J Respir Cell Mol Biol. 25:219-225 (2001). |
|
|
| |
|
|
|
| U6956 |
Uroguanylin, human |
0.5 mg |
$136.20 |
| |
C64H102N18O26S4 FW 1667.89 |
1 mg |
$231.20 |
| |
An endogenous ligand that binds and stimulates intestinal guanylate cyclase-C. |
2.5 mg |
$408.60 |
| |
Whitaker TL, Steinbrecher KA, Copeland NG, Gilbert DJ, Jenkins NA, Cohen MB. Genomics. 45: 348-54 (1997). |
|
|
| |
|
|
|
| U6957 |
Urotensin I |
0.5 mg |
$206.10 |
| |
C210H340N62O67S2 FW 4869.55 |
1 mg |
$351.20 |
| |
A neuroprotective that increase the survival rate of central and peripheral |
2.5 mg |
$620.00 |
| |
neuronons by activation of cAMP-dependent pathways. |
|
|
| |
Facci L,StevensDA,Pangallo M, Franceschini D, Skaper SD, Strijbos PJ. Neuropharmacology. 45: 623-36 (2003). |
|
|
| |
Marshall WS, Bern HA. Gen Comp Endocrinol. 43: 484-91 (1981). |
|
|
| |
|
|
|
| U6958 |
Urotensin II (Frog) |
0.5 mg |
$121.90 |
| |
C69H96N16O19S2 FW 1517.76 |
1 mg |
$207.90 |
| |
A neuropeptide that inhibits the active chloride transport of teleost fish. |
2.5 mg |
$365.60 |
| |
Marshall WS, Bern HA. Gen Comp Endocrinol. 43: 484-91 (1981). |
|
|
| |
|
|
|
| U6959 |
Urotensin II, human |
0.5 mg |
$121.90 |
| |
C64H85N13O18S2 FW 1388.6 |
1 mg |
$207.90 |
| |
|
2.5 mg |
$365.60 |
| |
|
|
|
| U6873 |
Ursodeoxycholic acid |
1 g |
$38.30 |
| |
C24H40O4 FW 392.57 m.p. 203-2040C [128-13-2] |
5 g |
$121.70 |
| |
A bile acid with significant chemopreventive activity in the colon. |
|
|
| |
Wali RK, Frawley BP, Hartmann S et al. Cancer Res. 55:5257-5264 (1995). |
|
|
| |
|
|
|
| U7354 |
Usnic acid |
5 g |
$33.90 |
| |
C18H16O7 FW 344.32 [125-46-2] |
25 g |
$123.00 |
| |
An antimicrobial, antitumor and enzyme inhibiting agent. Shown to uncouple oxidative |
|
|
| |
phosphorylation in mouse-liver mitochondria. Induces necrosis in certain cells. |
|
|
| |
Abo-Khatwa AN, al-Robai AA, al-Jawhari DA. Natural Toxins. 4:96-102 (1996). |
|
|
| |
Han D, Matsumaru K, Kettori D, Kaplowiz N. Biochem Pharm. 67:439-451 (2004). |
|
|
| |
|
|
|
| V0045 |
Valacyclovir Hydrochloride |
50 mg |
$65.30 |
| |
C13H20N6O4.HCl FW 360.80 [124832-27-5] |
100 mg |
$112.00 |
| |
L-valine ester of acyclovir that increases oral absorption before conversion to |
500 mg |
$456.40 |
| |
acyclovir. |
|
|
| |
Ormrod D, Scott LJ, Perry CM. Drugs. 59:839-63 (2000). |
|
|
| |
|
|
|
| |
|
|
|
| V0245 |
Valdecoxib |
5 mg |
$84.00 |
| |
C16H14N2O3S FW 314.36 [181695-72-7] |
10 mg |
$140.00 |
| |
A prescription drug used in the treatment of osteoarthritis, rheumatoid arthritis |
25 mg |
$280.00 |
| |
and it is classified as an NSAID. |
|
|
| |
Roumie, Christianne L. Stroke (2008), 39(7), 2037-2045. |
|
|
| |
|
|
|
| |
|
|
|
| V0147 |
Valproic Acid Sodium Salt |
10 g |
$24.10 |
| |
C8H15NaO2 FW 166.19 [1069-66-5] |
25 g |
$44.80 |
| |
Clinically used anti-convulsant and mood stabilizing drug. Used for epilepsy, |
100 g |
$123.20 |
| |
bipolar disorders. It is also used in the treatment of migraine headaches. |
|
|
| |
Mechanism of action is believed to be through the GABA neurotransmission pathways. |
|
|
| |
Quenby, S. M. European Journal of Obstetrics & Gynecology and Reproductive Biology (2008),137(1), 31-36. |
|
|
| |
|
|
|
| V0145 |
Valinomycin |
5 mg |
$34.50 |
| |
C54H90N6O18 FW 1111.32 [2001-95-8] |
10 mg |
$60.40 |
| |
A potassium ionophore that is well known to cause the collapse of the |
25 mg |
$109.40 |
| |
mitochondrial membrane potential, which precedes cytoplasmic acidification, |
|
|
| |
cysteine-active-site protease activation, DNA fragmentation and apoptotic cell death. |
|
|
| |
Inai Y, Yabuki M, Kanno T et al. Cell Struct Funct. 22:555-63 (1997). |
|
|
| |
Furlong IJ, Lopez Mediavilla C, Ascaso R et al. Cell Death Differ. 5:214-21 (1998). |
|
|
| |
|
|
|
| V0252 |
Vancomycin Hydrochloride |
100 mg |
$25.10 |
| |
C66H75Cl2N9O24.HCl FW 1485.73 [1404-93-9] |
250 mg |
$47.70 |
| |
A glycopeptide antibiotic that is commonly used for treatment of methicillin |
1 g |
$150.50 |
| |
resistant bacteria. It has been shown to inhibit glucose 6-phosphate dehydrogenase in vitro. |
|
|
| |
Beydemir S, Kulacoglu DN, Ciftci M, Kfrevioglu OI. Eur J Ophthal. 13:155-161 (2004). |
|
|
| |
Homer P, Peyman GA, Koziol J, Sanders D. Acta Ophthal. 53:311-320 (1975). |
|
|
| |
|
|
|
| V0153 |
Vanilloid Receptor Subtype 1 (VR1) |
1 mg |
$114.70 |
| |
C75H117N18O28S2 FW 1783.0 |
2 mg |
$195.30 |
| |
A heat-gated ion channel that mediates responses fo sensory neurons. |
5 mg |
$344.10 |
| |
Caterina MJ, Rosen TA, Tominaga M, Brake AJ, Julius D. Nature 398: 436-41 (1999). |
|
|
| |
|
|
|
| V0160 |
RC-160 (Vapreotide) |
0.5 mg |
$78.80 |
| |
C57H70N12O9S2 FW 1131.4 [103222-11-3] |
1 mg |
$134.40 |
| |
An octapeptide derivative of somatostatin (SRIF) capable of inhbiting growth |
2.5 mg |
$236.50 |
| |
in OV-1063 humanepithelial cancer cells. |
|
|
| |
Yano T, Radulovic S, Osuga Y et al. Oncology. 59 suppl 1:45-49 (2000) |
|
|
| |
|
|
|
| V0273 |
Vasoactive Intestinal peptide (VIP) |
0.5 mg |
$93.20 |
| |
C147H238N44O42S FW 3325.7 [40077-57-4] |
1 mg |
$157.70 |
| |
A neuropeptide that exhibits anti-inflamatory properties by inducing regulatory |
2.5 mg |
$279.60 |
| |
dendritic cells. |
|
|
| |
Gonzalez-Rey E, Delgado M. Gastroenterology. 131: 199-811 (2006). |
|
|
| |
|
|
|
| V3360 |
VIP, guinea pig |
0.5 mg |
$121.90 |
| |
Vasoactive Intestinal peptide, guinea pig |
1 mg |
$207.90 |
| |
C147H239N43O42S2 FW 3344.93 |
2.5 mg |
$365.60 |
| |
|
|
|
| V0274 |
[Lys8] Vasopressin |
1 mg |
$35.80 |
| |
C46H65N13O12S2 FW 1056.24 |
2 mg |
$60.90 |
| |
A neurohypophyseal peptide that mediates central and peripheral antidiuretic |
5 mg |
$107.50 |
| |
effects as a result of modifying four different G protein receptors. |
|
|
| |
Pena A, Murat B, Trueba M et. al. J Med Chem. 50: 835-47 (2007). |
|
|
| |
|
|
|
| V0275 |
[Arg8] Vasotocin |
1 mg |
$35.80 |
| |
C43H67N15O12S2 FW 1050.23 |
2 mg |
$60.90 |
| |
A neuropeptide hormone that controls water and salt metabolism. |
5 mg |
$107.50 |
| |
Leake RD, Weitzman RE. Clin Perinatol. 6: 65-85 (1979). |
|
|
| |
|
|
|
| V0376 |
Vatalanib Dihydrochloride |
5 mg |
$162.40 |
| |
C20H15ClN4.2HCl FW 419.73 [212141-54-3] |
10 mg |
$224.00 |
| |
Protein Kinase inhibitor under research for the treatment of solid tumors. |
25 mg |
$448.00 |
| |
Scott, E. N. Drugs of the Future (2007), 32(7), 607-613. |
|
|
| |
|
|
|
| V1810 |
Vecuronium Bromide |
10 mg |
$62.20 |
| |
C34H57BrN2O4 FW 637.74 [50700-72-6] |
50 mg |
$172.50 |
| |
A nonpolarizing neuromuscular relaxant. |
100 mg |
$276.00 |
| |
Marshall IG, Agoston S, Booij LH et al. Br J Anaesth. 52 Suppl 1:11S-19S (1980). |
|
|
| |
|
|
|
| V1854 |
Venlafaxine Hydrochloride |
500 mg |
$44.20 |
| |
C17H27NO2.HCl FW 313.87 [99300-78-4] |
1 g |
$71.80 |
| |
A heterocyclic antidepressant inhibits the re-uptake of serotonin, norepinephrine, |
5 g |
$296.70 |
| |
and dopamine. |
|
|
| |
Morton WA, Sonne SC, Verga MA. Ann Pharmacother. 29:387-95 (1995). |
|
|
| |
|
|
|
| V1769 |
(±)Verapamil Hydrochloride |
1 g |
$41.30 |
| |
C27N38N2O4.HCl FW 491.07 [152-11-4] |
5 g |
$124.00 |
| |
A calcium channel blocker with chemopreventive character. Verapamil was found to inhibit |
|
|
| |
carcinogen-induced aberrant crypt foci formation, mammary carcinogenesis, and pancreatic |
|
|
| |
carcinogenesis. |
|
|
| |
Wargovich MJ, Jimenez A, Mckee K et al. Carcinogenesis. 21:1149-55 (2000). |
|
|
| |
Soybir G, Koksoy F, Koyuncu H et al. Breast Cancer Res Treat. 50:193-9 (1998). |
|
|
| |
Nakaizumi A, Uehara H, Baba M et al. Cancer Lett. 105:23-7 9 (1996). |
|
|
| |
|
|
|
| V1870 |
Verruculogen |
1 mg |
$80.60 |
| |
C27H33N3O7 FW 511.567 [12771-72-1] |
5 mg |
$333.80 |
| |
A tremorgenic neurochemical produced by various soil fungi. |
|
|
| |
Paterson D, Shreeve B, Robberts B, MacDonald S, Appl Environ Microbiol. 42: 916-7 (1981). |
|
|
| |
Norris P, Smith C, De Belleroche J, Bradford H, Mantle P, Thomas A, Penny R. J Neurochem. 34: 33-42 (1980). |
|
|
| |
|
|
|
| V1872 |
Vesicular Stomatitis Virus peptide |
1 mg |
$35.80 |
| |
C44H66N12O12 FW 955.09 |
2 mg |
$66.30 |
| |
A antigenic peptide of vesicular stomatitis virus binds to H-2Kb antigens. |
5 mg |
$118.30 |
| |
Shibata K, Imarai M, van Bleek GM et. al. Proc Natl Acad Sci U S A. 89: 3135-9 (1992). |
|
|
| |
|
|
|
| V3212 |
Vidarabine |
100 mg |
$34.50 |
| |
C10H13N5O4 FW 267.24 [5536-17-4] |
500 mg |
$96.50 |
| |
Anti-leukemic agent. |
1 g |
$155.00 |
| |
Honma Y, Nitsu N. Leuk Lymphoma. 399:57-66 (2000). |
|
|
| |
|
|
|
| V3253 |
Vinblastine sulfate |
5 mg |
$79.20 |
| |
C46H59N4O9.HSO4 FW 909.05 m.p. 2670C [143-67-9] |
10 mg |
$143.40 |
| |
A vinca alkaloid isolated from Vinca rosea (periwinkle). It is an antimitotic agent |
|
|
| |
which binds to tubulin. Clinically used as an antitumor agent. |
|
|
| |
Gorman M et al. J Amer Chem Soc. 81:4745 (1959). |
|
|
| |
Mareel MM, De Brabander MJ. J Natl Cancer Inst. 61:787-92 (1978). |
|
|
| |
|
|
|
| V5254 |
Vincristine sulfate |
5 mg |
$137.10 |
| |
C46H57N4O10.HSO4 FW 923.04 m.p. >3000C [2068-39-4] |
10 mg |
$246.80 |
| |
An antimitotic agent which binds to tubulin. Clinically used as an antitumor agent. Induces apoptosis. |
|
|
| |
Mareel MM, Storme GA, De Bruyne GK, Van Cauwenberge RM. Eur J Cancer Clin Oncol. 18:199-210 (1982). |
|
|
| |
Harmon BV, Takano YS, Winterford CM, Potten CS. Cell Prolif. 25:523-36 (1992). |
|
|
| |
|
|
|
| V3354 |
Vindesine sulfate |
1 mg |
$79.00 |
| |
C43H55N5O7.H2SO4 FW 852.02 [59917-39-4] |
5 mg |
$303.60 |
| |
Vindesine, a vinca alkaloid derived from vinblastine. Potentially useful against a |
10 mg |
$531.30 |
| |
variety of solid and hematological malignancies. More often used in combination |
|
|
| |
regimens with cisplatin and ifosfamide. |
|
|
| |
Dancey J, Steward WP. Anticancer Drugs. 6:625-636 (1995). |
|
|
| |
Kodani T, Ueoka H, Kiura K et al. Lung Cancer. 36:313-319 (2002). |
|
|
| |
|
|
|
| V3355 |
Vindoline |
25 mg |
$57.80 |
| |
C25H32N2O6 FW 456.53 [2182-14-1] |
100 mg |
$148.80 |
| |
Monomeric vinca-alkaloid, forms lower portion of the lead anti-tumor agents, |
500 mg |
$569.30 |
| |
vinblastine and vincristine. Found to exhibit reciprocal cross-resistance to vincristine and vinblastine. |
|
|
| |
Fahy J. Curr Pharm Des. 7:1181-1197 (2001). |
|
|
| |
Inaba M, Nagashima K. Jpn J Cancer Res. 77:197-204 (1986). |
|
|
| |
|
|
|
| V3454 |
Vinleurosine sulfate |
10 mg |
$48.00 |
| |
C46H56N4O9.H2O4S FW 907.04 [54081-68-4] |
25 mg |
$100.00 |
| |
An antineoplastic agent. |
100 mg |
$320.00 |
| |
Gailani S D, Cancer chemotherapy reports. Part 1 (1966), 50(1), 95-103 |
|
|
| |
|
|
|
| V3251 |
Vinorelbine base |
1 mg |
$53.20 |
| |
C45H54N4O8 FW 778.93 [71486-22-1] |
5 mg |
$189.80 |
| |
Member of vinca-alkaloid. It is used in the treatment of anthracycline-resistent |
25 mg |
$736.30 |
| |
advanced breast cancer and recommended for the treatment of bronchial cancer. |
|
|
| |
Brown RE, Hutton J, Burrell A. Pharmacoeconomics. 19:1091-1102 (2001). |
|
|
| |
Ribet JP, Zalavari P, Commenges G et al. Ann Pharm Fr. 55:20-34 (1997). |
|
|
| |
|
|
|
| V3252 |
Vinorelbine Ditartrate |
1 mg |
$68.40 |
| |
C45H54N4O8.2C4H6O6 FW 1079.10 [125317-39-7] |
5 mg |
$220.20 |
| |
A chemotherapeutic agent effective against a number of solid tumors including non-small-cell |
25 mg |
$888.00 |
| |
carcinoma, advanced prostatic carcinoma, breast cancer, head and neck cancer, and Hodgkin's |
|
|
| |
lymphoma. It induces apoptosis and caspase-3 (CPP32) expression in leukemia and lymphoma cells. |
|
|
| |
Goa KL, Faulds D. Drugs Aging. 5:200-34 (1994). |
|
|
| |
Jones SF, Burris HA 3rd. Ann Pharmacother. 30:501-6 (1996). |
|
|
| |
Toh HC, Sun L, Koh CH, Aw SE. Leuk Lymphoma. 31:195-208 (1998). |
|
|
| |
|
|
|
| |
Vitamin A (See Retinol) |
|
|
| |
|
|
|
| |
Vitamin B6 (See pyridoxine HCl) |
|
|
| |
|
|
|
| V3378 |
Vitamin B12 |
500 mg |
$45.60 |
| |
C63H88CoN14O14P FW 1355.37 [68-19-9] |
1 g |
$75.90 |
| |
Also known as methylcobalamin/cobalamine. Prevents chronic diseases, |
5 g |
$250.50 |
| |
including cancer, coronary heart disease, and osteoporosis. |
|
|
| |
Fairfield KM, Fletcher RH. JAMA. 287:3116-31126 (2002). |
|
|
| |
Ames BN, Wakimoto P. Nat Rev Cancer. 2:694-704 (2002). |
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| V3476 |
Vitamin D2 |
1 g |
$77.60 |
| |
C28H44O FW 396.65 [50-14-6] |
5 g |
$303.90 |
| |
One of the vitamin D family. It is used in the treatment of refractory rickets (vitamin D resistant |
|
|
| |
rickets), familial hypophosphatemia and hypoparathyroidism. It also has a strong inhibitory effect |
|
|
| |
against bladder tumor promotion by sodium saccharin and induces cell differentiation in leukemia cells. |
|
|
| |
Yazawa Y, Yokota M, Sugiyama K, Biol Pharm Bull. 23:1298-302 (2000). |
|
|
| |
Yen A, Blue J, Forbes M. In vitro cell dev Biol. 27A:518-20 (1991). |
|
|
| |
|
|
|
| |
Vitamin D3 (See Cholecalciferol) |
|
|
| |
|
|
|
| V3276 |
Vitamin E, Natural |
100 g |
$78.40 |
| |
D-a-Tocopherol [10191-41-0] |
250 g |
$183.00 |
| |
It has been claimed that _-tocopherol is the most important lipid-soluble |
|
|
| |
antioxidant, and that it protects cell membranes from oxidation by reacting with |
|
|
| |
lipid radicals produced in the lipid peroxidation chain reaction |
|
|
| |
Marzani, B. Journal of Nutrition (2008), 138(11), 2205-2211. |
|
|
| |
Armagan, A. Basic & Clinical Pharmacology & Toxicology (2008), 103(2), 166-170. |
|
|
| |
|
|
|
| V3277 |
Vitamin E |
100 g |
$89.30 |
| |
D,L-a-Tocopherol |
250 g |
$201.60 |
| |
C29H50O2 FW 430.7 [2074-53-5] |
|
|
| |
An antioxidant and anticarcinogen toward a variety of cancers. |
|
|
| |
Wattenberg LW. Cancer Res. 45:1-8 (1985). |
|
|
| |
|
|
|
| V3479 |
Vitamin K3 |
10 g |
$17.10 |
| |
2-Methyl-1,4-naphthoquinone, menadione |
25 g |
$27.60 |
| |
C11H8O2 FW 172.18 [58-27-5] |
|
|
| |
Induces apoptosis in various cultured cells including leukemia cells. It has been shown that |
|
|
| |
vitamin K exerts anti-tumor activity by inhibiting cdk1 activity and over expressing the c-myc gene |
|
|
| |
to induce apoptotic cell death. Another hypothesis based on investigation done on the mode of |
|
|
| |
actions of vitamin K suggests that VK3 induces apoptosis by promoting the generation of intracellular |
|
|
| |
reactive oxygen intermediates and Fas/APO-1 expression. |
|
|
| |
Nishimaki J, Miyazawak, Yaguchi M et al. Leukemia. 13:1399-405 (1999). |
|
|
| |
Wu FY, Sun TP. Eur J Cancer. 35:1388-93 (1999). |
|
|
| |
Sun LK, Yoshii Y, Miyagi K. J Neurooncol. 47:31-8 (2000). |
|
|
| |
|
|
|
| W3576 |
Withaferin A |
1 mg |
$78.40 |
| |
C28H38O6 FW 470.6 [5119-48-2] |
5 mg |
$336.00 |
| |
An anti-cancer compound present in the roots and leaves of Withonia somnifera. |
|
|
| |
Displays marked tumor inhibiting activity. A novel angiogenesis inhibitor found in medicinal plants. |
|
|
| |
Mandal, C. Apoptosis (2008), 13(12), 1450-1464. |
|
|
| |
Oh, Jung Hwa. Apoptosis (2008), 13(12), 1494-1504. |
|
|
| |
|
|
|
| W0269 |
Warfarin |
1 g |
$13.40 |
| |
C19H16O4 FW 308.33 [81-81-2] |
10 g |
$84.00 |
| |
Used for preventing thrombosis and embolism. A synthetic derivative of |
25 g |
$156.80 |
| |
coumarin. Decreases blood coagulation by inhibiting vitamin K epoxide reductase. |
|
|
| |
Foerch, C. Stroke (2008), 39(12), 3397-3404. |
|
|
| |
|
|
|
| W0270 |
Warfarin Sodium |
1 g |
$24.60 |
| |
C19H15NaO4 FW 330.31 [129-06-6] |
10 g |
$162.40 |
| |
Used for preventing thrombosis and embolism. A synthetic derivative of |
25 g |
$296.80 |
| |
coumarin. Decreases blood coagulation by inhibiting vitamin K epoxide reductase. |
|
|
| |
Foerch, C. Stroke (2008), 39(12), 3397-3404. |
|
|
| |
|
|
|
| W4096 |
W-K-Y-M-V-M-NH2 |
0.5 mg |
$50.20 |
| |
C41H61N9O7S2 FW 856.13 |
1 mg |
$84.20 |
| |
A formyl peptide receptor-like 1 ligand, induces superoxide production by human neutrophils. |
2.5 mg |
$150.50 |
| |
Lee HY, Jo SH, Lee C, Baek SH, Bae YS. Biochem Pharmacol. 72: 860-8 (2006). |
|
|
| |
|
|
|
| W5726 |
Wogonin |
5 mg |
$72.80 |
| |
5,7-Dihydroxy-8-methoxyflavone |
10 mg |
$109.80 |
| |
C16H12O5 FW 248.26 [632-85-9] |
25 mg |
$246.40 |
| |
A flavanoid compound that exhibits cell apoptotic and cytotoxic effects in Bel-7402 cells. |
|
|
| |
This compound also demostrates anti-inflammatory and anti-cancer activities. |
|
|
| |
Yu JQ, Liu HB, Tian DZ, Liu YW, Lei JC, Zou GL. Hepatol Res. 37: 68-76 (2007). |
|
|
| |
Tai MC, Tsang SY, Chang LY, Xue H. CNS Drug Rev. 11:141-50 (2005). |
|
|
| |
|
|
|
| W5769 |
Wortmannin |
1 mg |
$59.20 |
| |
C23H24O8 FW 428.43 [19545-26-7] |
5 mg |
$233.60 |
| |
An inhibitor of PI3-K and DNA-dependent protein kinase, which is known to mediate DNA double |
|
|
| |
strand break repair. It induces apoptosis and also sensitizes cells to ionizing radiation. |
|
|
| |
Boulton S, Kyle S, Yalcintepe L, Durkacz BW. Carcinogenesis. 17: 2285 -90 (1996). |
|
|
| |
Ng SSW, Tsao MS, Chow S, Hedley DW. Cancer Res. 60: 5451-5 (2000). |
|
|
| |
Kubota N, Okada S, Inada T, Ohnishi K, Ohnishi T. Cancer Lett. 161:141-7 (2000). |
|
|
| |
|
|
|
| X1752 |
Xenin |
0.5 mg |
$136.20 |
| |
C139H224N38O32S1 FW 2971.63 |
1 mg |
$231.20 |
| |
An amphibian xenopsin-related peptide that stimulates exocrine pancreatic |
2.5 mg |
$408.60 |
| |
secretion. |
|
|
| |
Feurle GE, Hamscher G, Kusiek R, Meyer HE, Metzger JW. J Biol Chem. 267: 22305-9 (1991). |
|
|
| |
Hamscher G, Meyer HE, Metzger JW, Feurle GE. Peptides. 16: 791-7 (1995). |
|
|
| |
|
|
|
| X1753 |
Xenopsin |
1 mg |
$35.80 |
| |
C47H73N13O10 FW 980.19 |
2 mg |
$60.90 |
| |
|
5 mg |
$107.50 |
| |
|
|
|
| X1854 |
p-Xyleneselenocyanate, 99% |
100 mg |
$56.00 |
| |
|
250 mg |
$112.00 |
| |
C10H8N2Se2 FW 314.10 m.p. 1560C [85539-83-9] |
500 mg |
$194.70 |
| |
A synthetic organoselenium chemopreventive agent. |
|
|
| |
Found to inhibit chemically induced carcinogenesis |
|
|
| |
in the mammary glands, colon and lung of laboratory animals. |
|
|
| |
Tanaka T, Makita H, Kawabata K et al. Cancer Res. 57:3644-3648 (1997). |
|
|
| |
Prokopczyk B, Amin S, Desai DH et al. Carcinogenesis. 9:1855-1857 (1997). |
|
|
| |
|
|
|
| Y0052 |
Yangonin |
5 mg |
$111.40 |
| |
C15H14O4 FW 258.27 [500-62-9] |
10 mg |
$172.10 |
| |
One of the major components of kava extract reported to have |
|
|
| |
binding affinities to CNS receptors. |
|
|
| |
Dinh LD, Simmen U, Bueter KB. Planta Med. 67:306-11 (2001). |
|
|
| |
|
|
|
| Z0146 |
Z-Ala-Ala-Leu-pNA |
100 mg |
$89.60 |
| |
C26H33N5O7 FW 527.6 [61043-33-2] |
250 mg |
$179.20 |
| |
|
|
|
| |
Zalcitabine (See 2',3'-Dideoxycytidine) |
|
|
| |
C9H13N3O3 FW 211.22 [7481-89-2] |
|
|
| |
An anti-HTLV-III/LAV drug. |
|
|
| |
|
|
|
| Z1216 |
Z-D-E-V-D-AMC |
5 mg |
$207.90 |
| |
Ac-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin |
10 mg |
$353.00 |
| |
C36H41N5O14 FW 767.0 |
25 mg |
$623.60 |
| |
A fluorogenic peptide substrate used to determine caspase activties. |
|
|
| |
Haviv R, Lindenboim L, Li H, Yuan J, Stein R. J Neurosci Res. 50: 69-80 (1997). |
|
|
| |
|
|
|
| Z2268 |
Z-F-R-AMC |
10 mg |
$164.90 |
| |
C33H36N6O6 FW 621.58 |
20 mg |
$279.60 |
| |
A peptide substrate used to experimentally determine cathepsin B and L activities. |
50 mg |
$494.60 |
| |
Li Y. et. al. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 16: 101-4 (1998). |
|
|
| |
|
|
|
| Z6269 |
Z-Pro-D-Leu |
10 mg |
$71.70 |
| |
C19H26N2O5 FW 362.4 |
20 mg |
$121.90 |
| |
A synthetic peptide derived from the c-terminus fragment of oxytocin. It is an |
50 mg |
$215.00 |
| |
effective inhibitor of tolerance to and dependence on morphine in mice. |
|
|
| |
Kovacs GL, Acsai L, Tihanyi A, Faludi M, Telegdy G. Pharmacol Biochem Behav. 18: 345-9 (1983). |
|
|
| |
|
|
|
| Z1602 |
Zearalenone |
1 mg |
$22.40 |
| |
C18H22O5 FW 318.36 [17924-92-4] |
5 mg |
$44.80 |
| |
An estrogenic mycotoxin produced by genus Fusarium found in cerea grains. |
10 mg |
$80.60 |
| |
Zearalenone induced apoptosis and proliferation in granusola cells from |
|
|
| |
cycling mare ovaries. |
|
|
| |
Tiemann U, Danicke S. Food Addit Contam. 24: 306-14 (2007). |
|
|
| |
Minervini F, Giannoccaro A, Fornelli F. et. al. Reprod Biol Endocrinol. 4: 62 (2006). |
|
|
| |
|
|
|
| |
Zidovudine (See 3'-Azido-3'-deoxythymidine (AZT)) |
|
|
| |
|
|
|
| Z5744 |
Zoledronic acid |
10 mg |
$56.00 |
| |
C5H10N2O7P2 FW 272.09 [118072-93-8] |
25 mg |
$112.00 |
| |
A potent bone resorption inhibitor. May improve osteosarcoma treatments when |
100 mg |
$336.00 |
| |
administered with anticancer agents. |
|
|
| |
Schortinghuis J, Witjes MJ, Spijkervet KL, de Visscher JG. Ned Tijdschr Geneeskd. 151:314-8 (2007). |
|
|
| |
Horie N et. al.Br J Cancer. 96: 255-61 (2007). |
|
|
| |
|
|
|
| Z5653 |
Zonisamide |
10 mg |
$100.40 |
| |
C8H8N2O3S FW 212.23 [68291-97-4] |
25 mg |
$188.20 |
| |
A new-generation antiepileptic drug (AED) with applications as an |
100 mg |
$627.20 |
| |
antinocireceptive agent. |
|
|
| |
Sakaue A, Honda M, Tanabe M, Ono H. J Pharm Sci. 95:181-8 (2004). |
|
|
| |
Low PA, James S, Peschel T et al. J Neur. 251:1043-9 (2004). |
|
|
| |
|
|
|
